Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2025 Annual Scientific Meeting
Phathom Pharmaceuticals, Inc. (PHAT)
Last phathom pharmaceuticals, inc. earnings: 3/19 08:31 am
Check Earnings Report
Company Research
Source: GlobeNewswire
FLORHAM PARK, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced its participation in the American College of Gastroenterology’s (ACG) 2025 Annual Scientific Meeting, being held October 24-29 in Phoenix, Arizona. Phathom will showcase its growing leadership in GI through multiple engagements with the medical and scientific community, including a product theater presentation highlighting VOQUEZNA® (vonoprazan) tablets as an approved treatment for Gastroesophageal Reflux Disease (GERD) and a prominent presence on the exhibit floor. “We are excited to build on the growing momentum for VOQUEZNA in the treatment of GERD by connecting with the GI community at ACG,” said Steve Basta, President and Chief Executive Officer of Phathom. “Meetings like ACG provide an opportunity to share clinical insights, engage with exp
Show less
Read more
Impact Snapshot
Event Time:
PHAT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PHAT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PHAT alerts
High impacting Phathom Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
PHAT
News
- Phathom Pharmaceuticals (NASDAQ:PHAT) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.MarketBeat
- Should Phathom's US$130 Million Equity Raise and Profitability Timeline Update Require Action From Phathom Pharmaceuticals (PHAT) Investors? [Yahoo! Finance]Yahoo! Finance
- Phathom: Why I'm Not Buying The Dip (Yet) [Seeking Alpha]Seeking Alpha
- Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewswire
- Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewswire
PHAT
Earnings
- 10/30/25 - Beat
PHAT
Sec Filings
- 1/15/26 - Form 4
- 1/8/26 - Form 8-K
- 1/8/26 - Form 424B5
- PHAT's page on the SEC website